JP2018522831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522831A5 JP2018522831A5 JP2017562029A JP2017562029A JP2018522831A5 JP 2018522831 A5 JP2018522831 A5 JP 2018522831A5 JP 2017562029 A JP2017562029 A JP 2017562029A JP 2017562029 A JP2017562029 A JP 2017562029A JP 2018522831 A5 JP2018522831 A5 JP 2018522831A5
- Authority
- JP
- Japan
- Prior art keywords
- chemical entity
- ring
- ocf
- carbon atom
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000005829 chemical entities Chemical class 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 2
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169107P | 2015-06-01 | 2015-06-01 | |
| US62/169,107 | 2015-06-01 | ||
| PCT/US2016/035098 WO2016196513A1 (en) | 2015-06-01 | 2016-05-31 | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522831A JP2018522831A (ja) | 2018-08-16 |
| JP2018522831A5 true JP2018522831A5 (enExample) | 2019-07-04 |
| JP6876625B2 JP6876625B2 (ja) | 2021-05-26 |
Family
ID=57441824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562029A Active JP6876625B2 (ja) | 2015-06-01 | 2016-05-31 | Ｎｒ２ｂｎｍｄａレセプターアンタゴニストとしての３，３−ジフルオロピペリジンカルバメート複素環式化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10584127B2 (enExample) |
| EP (1) | EP3303323B1 (enExample) |
| JP (1) | JP6876625B2 (enExample) |
| KR (1) | KR102613179B1 (enExample) |
| CN (1) | CN107849010B (enExample) |
| AR (1) | AR104837A1 (enExample) |
| AU (1) | AU2016270677B2 (enExample) |
| BR (1) | BR112017025023B1 (enExample) |
| CA (1) | CA2987606C (enExample) |
| DK (1) | DK3303323T3 (enExample) |
| ES (1) | ES2784398T3 (enExample) |
| IL (1) | IL255937B (enExample) |
| MX (1) | MX380424B (enExample) |
| RU (1) | RU2735277C2 (enExample) |
| TW (1) | TWI721987B (enExample) |
| WO (1) | WO2016196513A1 (enExample) |
| ZA (1) | ZA201708006B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CA2987606C (en) | 2015-06-01 | 2024-02-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| CN106986874B (zh) * | 2016-01-20 | 2019-09-24 | 西华大学 | (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途 |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| IL297333B2 (en) | 2020-04-17 | 2025-09-01 | Honeybrains Llc | Preparations and methods for treating neuropsychiatric disorders |
| CN117159541B (zh) * | 2023-09-20 | 2026-05-26 | 南华大学 | Nat10拮抗剂在制备预防和/或治疗癫痫的药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3717867A1 (de) | 1987-05-26 | 1988-12-15 | Schiepe Stapelautomaten Gmbh | Stapelvorrichtung |
| IL122649A (en) | 1995-08-11 | 2001-08-26 | Pfizer | (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same |
| GB9805977D0 (en) * | 1998-03-19 | 1998-05-20 | Silver Joshua D | Improvements in variable focus optical devices |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| MXPA03007621A (es) | 2001-02-23 | 2003-12-04 | Merck & Co Inc | Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos. |
| KR20060017839A (ko) * | 2003-06-04 | 2006-02-27 | 머크 앤드 캄파니 인코포레이티드 | Ｎｍｄａ／ｎｒ2ｂ 길항제로서 3-플루오로-피페리딘 |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| US20070293515A1 (en) | 2004-08-03 | 2007-12-20 | Layton Mark E | 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists |
| CA2591738A1 (en) * | 2004-12-22 | 2006-06-29 | Merck & Co., Inc. | Process for making substituted piperidines |
| CA2603876A1 (en) | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CA2662702A1 (en) * | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Difluorinated piperidines for treatment of alzheimer's disease and related conditions |
| KR20090094338A (ko) | 2006-12-27 | 2009-09-04 | 사노피-아벤티스 | 치환된 이소퀴놀린 및 이소퀴놀리논 유도체 |
| US20110053951A1 (en) | 2008-03-27 | 2011-03-03 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| US20100010565A1 (en) * | 2008-07-09 | 2010-01-14 | Samuel Victor Lichtenstein | Extended range wireless muscular and neural stimulation |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| EP2519241A2 (en) | 2009-12-28 | 2012-11-07 | Afraxis, Inc. | Methods for treating autism |
| ES2734552T3 (es) * | 2010-04-16 | 2019-12-10 | Ac Immune Sa | Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide |
| US20130231348A1 (en) | 2010-06-09 | 2013-09-05 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011159945A2 (en) | 2010-06-16 | 2011-12-22 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| JP6007417B2 (ja) | 2011-05-31 | 2016-10-12 | レセプトス エルエルシー | 新規ｇｌｐ−１受容体安定剤および調節剤 |
| AU2013251079B2 (en) * | 2012-04-20 | 2017-03-23 | Ucb Pharma S.A. | Methods for treating Parkinson's disease |
| EA029056B1 (ru) * | 2012-12-11 | 2018-02-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| JP2017500287A (ja) * | 2013-11-06 | 2017-01-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体 |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| BR112016025910A8 (pt) | 2014-05-06 | 2021-07-13 | Univ Northwestern | uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos |
| US10030026B2 (en) | 2014-06-04 | 2018-07-24 | Rugen Holdings (Cayman) Limited | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists |
| MX2017002775A (es) | 2014-09-15 | 2017-08-10 | Rugen Holdings (Cayman) Ltd | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. |
| US20180271869A1 (en) | 2014-09-22 | 2018-09-27 | Jie Liu | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| CA2987606C (en) | 2015-06-01 | 2024-02-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2016
- 2016-05-31 CA CA2987606A patent/CA2987606C/en active Active
- 2016-05-31 MX MX2017015370A patent/MX380424B/es unknown
- 2016-05-31 EP EP16804257.0A patent/EP3303323B1/en active Active
- 2016-05-31 AU AU2016270677A patent/AU2016270677B2/en active Active
- 2016-05-31 BR BR112017025023-3A patent/BR112017025023B1/pt active IP Right Grant
- 2016-05-31 CN CN201680042502.8A patent/CN107849010B/zh active Active
- 2016-05-31 TW TW105117083A patent/TWI721987B/zh active
- 2016-05-31 AR ARP160101591A patent/AR104837A1/es unknown
- 2016-05-31 JP JP2017562029A patent/JP6876625B2/ja active Active
- 2016-05-31 US US15/578,460 patent/US10584127B2/en active Active
- 2016-05-31 KR KR1020177037807A patent/KR102613179B1/ko active Active
- 2016-05-31 RU RU2017142005A patent/RU2735277C2/ru active
- 2016-05-31 WO PCT/US2016/035098 patent/WO2016196513A1/en not_active Ceased
- 2016-05-31 DK DK16804257.0T patent/DK3303323T3/da active
- 2016-05-31 ES ES16804257T patent/ES2784398T3/es active Active
-
2017
- 2017-11-24 ZA ZA2017/08006A patent/ZA201708006B/en unknown
- 2017-11-27 IL IL255937A patent/IL255937B/en active IP Right Grant
-
2018
- 2018-08-10 US US16/100,596 patent/US10294230B2/en active Active
-
2020
- 2020-03-05 US US16/810,258 patent/US11136328B2/en active Active
-
2021
- 2021-10-01 US US17/491,676 patent/US20220024937A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017142005A (ru) | 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора | |
| JP2020517711A5 (enExample) | ||
| JP2019522007A5 (enExample) | ||
| JP2022505835A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2021535112A5 (enExample) | ||
| JP2016179996A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2018529739A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2023522177A5 (enExample) | ||
| JP2013520473A5 (enExample) | ||
| JP2010523709A5 (enExample) | ||
| KR20210029790A (ko) | PIKfyve 저해제 | |
| JP2005530811A5 (enExample) | ||
| JP2012508251A5 (enExample) | ||
| JP2020520957A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| JP2025511122A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2005511545A5 (enExample) | ||
| JP2020128426A5 (enExample) | ||
| JP2007522142A5 (enExample) |